Global Diabetic Macular Edema Market Report By Product (Intravitreal Injections, Intravitreal Implants), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2022-2030
The global demand for Diabetic Macular Edema Market is presumed to reach the market size of nearly USD 14.42 BN by 2030 from USD 9.21 BN in 2022 with a CAGR of 5.76% under the study period 2023 - 2030.
Diabetic macular oedema (DME) is a diabetic retinopathy complication, which is a condition that affects the eyes of individuals with diabetes. DME specifically refers to the accumulation of fluid in the macula, the central part of the retina responsible for sharp and detailed vision.
The increasing prevalence of diabetes, particularly type 2 diabetes, is a significant driver as it raises the probability of developing Diabetic macular oedema (DME). The ageing population is another contributing factor, as age-related macular degeneration and diabetic retinopathy, including DME, become more common in older individuals. Improved screening and diagnostic technologies have led to earlier detection and diagnosis of DME, resulting in increased treatment rates. Advancements in treatment options, such as anti-VEGF drugs and sustained-release drug delivery systems, have expanded the choices available for managing this condition and improving visual outcomes. Increasing healthcare expenditure, supportive regulatory frameworks, and favourable reimbursement policies play a crucial role in market growth. Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters innovation and drives research in the field.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic macular edema. The growth and trends of diabetic macular edema industry provide a holistic approach to this study.
This section of the diabetic macular edema market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Distribution Channel
This section covers the regional outlook, which accentuates current and future demand for the Diabetic Macular Edema market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Diabetic Macular Edema Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the diabetic macular edema market include Pfizer Inc., Allergan PLC, Novartis AG, Clearside Biomedical Inc, Ariam Pharmaceuticals, Valeant Pharmaceuticals, Regenron PLC, Bayer AG, pSivida Corporation, Alimera Sciences Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . DIABETIC MACULAR EDEMA – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Product
3.7.2 Market Attractiveness Analysis By Distribution Channel
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL DIABETIC MACULAR EDEMA MARKET ANALYSIS BY PRODUCT
5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Intravitreal Injections Historic and Forecast Sales by Regions
5.5 Intravitreal Implants Historic and Forecast Sales by Regions
6 . GLOBAL DIABETIC MACULAR EDEMA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Retail Pharmacies Historic and Forecast Sales by Regions
6.5 Hospital Pharmacies Historic and Forecast Sales by Regions
7 . GLOBAL DIABETIC MACULAR EDEMA MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outl ...
Frequently Asked Questions (FAQs) about this Report
The Global Diabetic Macular Edema Market size was worth USD 9.21 Billion in 2022.
For the years 2023-2030, the Global Diabetic Macular Edema Market growth is expected to be around 5.76%.
The Global Diabetic Macular Edema Market is currently dominated by North America.
The Global Diabetic Macular Edema Market is segmented by Product (Intravitreal Injections, Intravitreal Implants), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies).
The leading players in the Global Diabetic Macular Edema Market are Pfizer Inc., Allergan PLC, Novartis AG, Clearside Biomedical Inc, Ariam Pharmaceuticals, Valeant Pharmaceuticals, Regenron PLC, Bayer AG, pSivida Corporation, Alimera Sciences Inc.